artemether has been researched along with Adverse Drug Event in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Efferth, T; Kaina, B | 1 |
| Andriano, K; De Palacios, PI; Falade, C; Hunt, P; Karbwang, J; Makanga, M; Mueller, EA; Premji, Z | 1 |
2 review(s) available for artemether and Adverse Drug Event
| Article | Year |
|---|---|
Toxicity of the antimalarial artemisinin and its dervatives.
Topics: Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Clinical Trials as Topic; Developing Countries; Dogs; Drug Administration Routes; Drug-Related Side Effects and Adverse Reactions; Humans; Malaria; Rabbits; Rats; Sesquiterpenes | 2010 |
Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.
Topics: Animals; Antimalarials; Artemether; Artemisinins; Body Weight; Child; Child, Preschool; Clinical Trials as Topic; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Ethanolamines; Female; Fever; Fluorenes; Humans; Infant; Life Cycle Stages; Lumefantrine; Malaria, Falciparum; Male; Time Factors | 2006 |
1 other study(ies) available for artemether and Adverse Drug Event
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |